✦ LIBER ✦

Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery

✍ Scribed by Vauthier, Christine; Labarre, Denis; Ponchel, Gilles

Book ID: 120230417
Publisher: Informa plc
Year: 2007
Tongue: English
Weight: 525 KB
Volume: 15
Category: Article
ISSN: 1061-186X
DOI: 10.1080/10611860701603372

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Design aspects of poly(alkylcyanoacrylat

Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery

✍ Vauthier, Christine; Labarre, Denis; Ponchel, Gilles 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 525 KB

Magnetite/poly(alkylcyanoacrylate) (core

Magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles as 5-Fluorouracil delivery systems for active targeting

✍ José L. Arias; Visitación Gallardo; Ma Adolfina Ruiz; Ángel V. Delgado 📂 Article 📅 2008 🏛 Elsevier Science 🌐 French ⚖ 307 KB

The radiation stability of an ampicillin

The radiation stability of an ampicillin drug based on poly(alkylcyanoacrylate) nanoparticles

✍ D. V. Paramonov; E. A. Antonova; N. G. Zharova; S. é. Gel'perina; K. A. Stolbova 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 303 KB

Nanoparticle Technology Handbook || Desi

Nanoparticle Technology Handbook || Design of nanoparticles for oral delivery of peptide drugs

✍ Ichikawa, Hideki 📂 Article 📅 2012 🏛 Elsevier ⚖ 468 KB

Combined hydroxypropyl-β-cyclodextrin an

Combined hydroxypropyl-β-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir

✍ H Boudad; P Legrand; G Lebas; M Cheron; D Duchêne; G Ponchel 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 286 KB

Degradable Poly(β-amino ester) nanoparti

Degradable Poly(β-amino ester) nanoparticles for cancer cytoplasmic drug delivery

✍ Youqing Shen; Huadong Tang; Yihong Zhan; Edward A. Van Kirk; William J. Murdoch 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 794 KB

Fast cytoplasmic drug delivery can overcome cancer cells' drug resistance and thus have an enhanced therapeutic efficacy. Such a drug delivery regime requires drug carriers capable of entering cancer cells, localizing and rapidly releasing the drug into endosomes/lysosomes, and subsequently disrupti